In vivo studies involving gene editing with CRISPR-Cas9 and lentiviral vectors have produced promising results, including the correction of the mutation that causes SCD, as well as increased HbF levels through the disruption of the BCL11A gene [11,12]. Here, BCL11A is linked to Schnyder corneal dystrophy.